Active, not recruitingPhase 2NCT03728972
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
Studying Extranodal nasal NK/T cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Alison Moskowitz, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Pembrolizumab(drug)
- Enrollment
- 19 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2026
Study locations (10)
- Stanford University, Stanford, California, United States
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Hackensack Meridian Health, Hackensack, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
- Md Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03728972 on ClinicalTrials.govOther trials for Extranodal nasal NK/T cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07380984PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCLRuijin Hospital
- RECRUITINGPHASE1, PHASE2NCT06966154A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCLFudan University
- RECRUITINGPHASE2NCT07000617A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell LymphomaPeking University Cancer Hospital & Institute
- RECRUITINGPHASE1NCT06732492RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell MalignanciesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ENROLLING BY INVITATIONNCT07450040Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell LymphomaEye & ENT Hospital of Fudan University
- RECRUITINGPHASE1, PHASE2NCT06559553"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCLMingzhi Zhang
- RECRUITINGPHASE2NCT06824883Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell LymphomaPeking Union Medical College Hospital
- RECRUITINGPHASE1, PHASE2NCT06376721Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaBeijing Tongren Hospital